Project: Targeted alpha therapy in the treatment of ovarian cancer

Acronym TAT-OV-ASTATINE-2 (Reference Number: 11435)
Duration 01/09/2017
Project Topic The idea of this project is to develop a targeted alpha-particle radio-immunotherapy (TAT) based on astatine conjugated to the monoclonal antibody (MAb) farletuzumab as a new drug for the treatment of ovarian cancer. We will conduct the First-in-Man clinical trial in patients in complete clinical remission after second-line chemotherapy for recurrent ovarian carcinoma. The aim is to study pharmacokinetics (PK) and particularly bio-distribution; as well as safety and toxicity.
Network Eurostars 2
Call Eurostars Cut-Off 7

Project partner

Number Name Role Country
1 Smerud Medical Research International AS Coordinator Norway
2 Sahlgrenska University Hospital Partner Sweden